share_log

Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $200

Benzinga ·  Apr 25 14:02

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $215 to $200.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment